INS and Insulin resistance: In phase 2a trials in obese and dyslipidemic or obese and prediabetic patients, 80 mg/d elafibranor consistently improved plasma lipids (decrease in plasma triglycerides and LDL-cholesterol, increase in HDL-cholesterol), improved glucose homeostasis (decrease in plasma glucose, fructosamine, insulin and HOMA-IR, improvement of hepatic and peripheral insulin resistance during hyperinsulinemic euglycemic clamps) and in addition improved the levels of liver enzymes (plasma alanine aminotransferase, alkaline phospatase and γ-glutamyltransferase)46,47.